Category: Regulatory/FDA

CHC_FDA-Regulatory Images1

11/30/2017

OPDP’s Third Enforcement Letter of 2017 Cites Presentation of Risks, Efficacy Claims

CHC_general2

10/30/2017

Gottlieb: FDA Has Vital Role to Play in Addressing Opioid Crisis

CHC_general1

09/08/2017

OPDP Issues Warning Letter for Omission of Risks, Material Facts

CHC_FDA-Regulatory Images1

09/05/2017

FDA Study of Promotion Disclosure Needs to Address First Amendment, Other Issues

CHC_FDA-Regulatory Images1

06/12/2017

Gottlieb Asserts FDA Authority in Considering Opioid Risks

CHC_FDA-Regulatory Images2

06/01/2017

OPDP Issues First Enforcement Letter of 2017

05/31/2017

Pines: FDA’s Gottlieb Will First Tackle Administrative Issues

05/01/2017

Gottlieb Vote Headed to Full Senate

CHC_FDA-Regulatory Images1

03/20/2017

Gottlieb Is “Known” Entity to Pharma Industry